Nimotuzumab

Nimotuzumab is a recombinant humanized monoclonal antibody that binds to the extracellular domain of the human epidermal growth factor receptor 2 (HER2). It is a chimeric antibody consisting of an Fc portion from human IgG1 and a variable region from murine IgG1. Nimotuzumab is produced through mammalian cell culture of non-secreting NS0 cells and has a molecular weight of 151,000.

Clinical Pharmacology
Nimotuzumab binds to the HER2 receptor with high affinity and specificity to the extracellular domain of the epidermal growth factor receptor 2 (EGFR). It is used in combination with standard chemotherapies or radiation therapy to treat HER2-positive breast cancer and colorectal cancer.

Nimotuzumab is administered as an intravenous infusion over 1 hour. It is indicated for the treatment of HER2-positive breast cancer and colorectal cancer.

Indications
- Treatment of HER2-positive breast cancer
- Treatment of metastatic colorectal cancer

Dosage
- Intravenous infusion over 1 hour

Contraindications
- Hypersensitivity to nimotuzumab
- Concurrent use of trastuzumab

Warnings
- Myelosuppression
- Thrombocytopenia
- Neutropenia

Precautions
- Monitor for infusion reactions
- Monitor for neutropenia

Drug Interactions
- Avoid concomitant use with trastuzumab

Overdose
- Symptoms may include fever, chills, flushing, dyspnea, hypotension, and shock

Storage Conditions
- Store at 2-8°C

Presentations
- 10 mg/mL solution for infusion

On Medical Prescription Only

Manufactured by:
Center of Molecular Immunology
Havana, Cuba

For,
Innogenex Kalbitzho Pte. Ltd.